Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Mar;43(3):350–354. doi: 10.1038/bjc.1981.55

Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate.

J S Mahood, R L Willson
PMCID: PMC2010608  PMID: 7225286

Abstract

The cytotoxic activity of metronidazole (Flagyl) and misonidazole (MISO) to hypoxic Chinese hamster ovary (CHO) cells suspended in standard medium in sealed vials and in gassed spinner flasks has been investigated. Flagyl (5 mM) was only cytotoxic at high initial cell densities. However, when lactate (20 mM) was included in the medium the cytotoxicity of Flagyl at low cell densities was considerable, and similar to that of misonidazole under the same conditions. The relevance of this "lactate effect" to in vivo systems, and the possible mechanisms involved, are discussed.

Full text

PDF
350

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Stratford I. J., Wallace R. G., Wardman P., Watts M. E. Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential. J Natl Cancer Inst. 1980 Mar;64(3):555–560. [PubMed] [Google Scholar]
  2. Basag S. H., Dunlop J. R., Searle A. J., Willson R. L. Metronidazole (flagyl) and misonidazole (Ro-07-0582): reduction by facultative anaerobes and cytotoxic action on hypoxic bacteria and mammalian cells in vivo. Br J Cancer Suppl. 1978 Jun;3:132–135. [PMC free article] [PubMed] [Google Scholar]
  3. Denekamp J., Michael B. D., Harris S. R. Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974 Oct;60(1):119–132. [PubMed] [Google Scholar]
  4. Dische S., Gray A. J., Zanelli G. D. Clinical testing of the radiosensitiser Ro-07-0582. II. Radiosensitisation of normal and hypoxic skin. Clin Radiol. 1976 Apr;27(2):159–166. doi: 10.1016/s0009-9260(76)80138-9. [DOI] [PubMed] [Google Scholar]
  5. Dische S., Saunders M. I. Clinical experience with misonidazole. Br J Cancer Suppl. 1978 Jun;3:311–313. [PMC free article] [PubMed] [Google Scholar]
  6. Foster J. L., Conroy P. J., Searle A. J., Willson R. L. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer. 1976 May;33(5):485–490. doi: 10.1038/bjc.1976.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Foster J. L., Willson R. L. Radiosensitization of anoxic cells by metronidazole. Br J Radiol. 1973 Mar;46(543):234–235. doi: 10.1259/0007-1285-46-543-234. [DOI] [PubMed] [Google Scholar]
  8. Hall E. J., Astor M., Geard C., Biaglow J. Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamine. Br J Cancer. 1977 Jun;35(6):809–815. doi: 10.1038/bjc.1977.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hall E. J., Miller R., Astro M., Rini F. The nitroimidazoles as radiosensitizers and cytotoxic agents. Br J Cancer Suppl. 1978 Jun;3:120–123. [PMC free article] [PubMed] [Google Scholar]
  10. Johnson R., Gomer C., Pearce J. An investigation of the radiosensitizing effects of Ro-07-0582 on hypoxic skin in primates. Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):593–599. doi: 10.1016/0360-3016(76)90140-1. [DOI] [PubMed] [Google Scholar]
  11. Mohindra J. K., Rauth A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976 Mar;36(3):930–936. [PubMed] [Google Scholar]
  12. Prince H. N., Grunberg E., Titsworth E., DeLorenzo W. F. Effects of l-(2-nitro-l-imidazolyl)-3-methoxy-2-propanol and 2-methyl-5-nitroimidazole-l-ethanol against anaerobic and aerobic bacteria and protozoa. Appl Microbiol. 1969 Nov;18(5):728–730. doi: 10.1128/am.18.5.728-730.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shapot V. S. Some biochemical aspects of the relationship between the tumor and the host. Adv Cancer Res. 1972;15:253–286. doi: 10.1016/s0065-230x(08)60377-2. [DOI] [PubMed] [Google Scholar]
  14. Sridhar R., Koch C., Suterland R. Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model. Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1149–1157. doi: 10.1016/0360-3016(76)90088-2. [DOI] [PubMed] [Google Scholar]
  15. Stone H. B., Withers H. R. Tumor and normal tissue response to metronidazole and irradiation in mice. Radiology. 1974 Nov;113(2):441–444. doi: 10.1148/113.2.441. [DOI] [PubMed] [Google Scholar]
  16. Stratford I. J. Split dose cytotoxic experiments with misonidazole. Br J Cancer. 1978 Jul;38(1):130–136. doi: 10.1038/bjc.1978.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sutherland R. M. Selective chemotherapy of noncycling cells in an in vitro tumor model. Cancer Res. 1974 Dec;34(12):3501–3503. [PubMed] [Google Scholar]
  18. Taylor Y. C., Rauth A. M. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 1978 Sep;38(9):2745–2752. [PubMed] [Google Scholar]
  19. Urtasun R. C., Chapman J. D., Band P., Rabin H. R., Fryer C. G., Sturmwind J. Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. Radiology. 1975 Oct;117(1):129–133. doi: 10.1148/117.1.129. [DOI] [PubMed] [Google Scholar]
  20. Whillans D. W., Rauth A. M. An analysis of changes in oxygen tension in stirred cellular suspensions under conditions of radiolytic and cellular consumption. Cancer Clin Trials. 1980 Spring;3(1):63–67. [PubMed] [Google Scholar]
  21. Willson R. L., Cramp W. A., Ings R. M. Metronidazole ('Flagyl'): mechanisms of radiosensitization. Int J Radiat Biol Relat Stud Phys Chem Med. 1974 Dec;26(6):557–569. doi: 10.1080/09553007414551591. [DOI] [PubMed] [Google Scholar]
  22. Wiltshire C. R., Workman P., Watson J. V., Bleehen N. M. Clinical studies with misonidazole. Br J Cancer Suppl. 1978 Jun;3:286–289. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES